Servier and Aitia enter into R&D collaboration for pancreatic cancer using Digital Twins

Research & Development

French pharmaceutical company Servier and US-based Causal AI and Digital Twins company Aitia have announced a collaboration to create Digital Twins as an aid to help treat pancreatic cancer. This collaboration builds on a previous multiple myeloma one that was announced in 2022.

Gemini Digital Twins brings together omics and patient data into an AI-powered system that is used to discover genetic and molecular pathways linked to clinical outcomes of a specific disease. It works by modelling what happens when a gene or protein is targeted, which can reveal new drug indications. The platform also allows the simulation of disease progression and response to drug therapies.

Under the terms of the agreement, Aitia and Servier will discover, validate and strive to develop novel drug targets through Aitia’s Gemini Digital Twins and Servier’s preclinical assays, therapeutic creation platforms and expertise. Servier will then receive an exclusive option to research, develop and commercialise products stemming from the collaboration.

Claude Bertrand, executive VP of Research and Development and chief scientific officer at Servier, stated: “I am convinced that scientific innovation combined with the power of digital technologies will help us bring new and innovative treatments faster to patients suffering from difficult and hard-to-treat cancers. Our expanded collaboration with Aitia will leverage discoveries from Gemini Digital Twins and harness the full potential of AI to make significant strides towards developing deeper biology of the disease and a better understanding of translational medicine questions such as biomarkers, patient stratifications or the discovery of drug targets. We believe this approach will generate novel mechanisms and hypotheses for potential new targeted therapies that can make a meaningful difference in the lives of patients with pancreatic cancer.”

Colin Hill, CEO and co-founder of Aitia, commented: “Pancreatic cancer is one of the most devastating cancers that claims the lives of far too many people far too soon. Drug discovery and development efforts in pancreatic cancer to date have yielded very few treatment options for patients. We believe our Gemini Digital Twins, which are created from large quantities of multi-omic patient data and Causal AI, have the potential to bring significant disruption to the field of pancreatic cancer and pave the way for breakthrough discoveries. We’re excited to collaborate with Servier to gain deeper insights into the underlying mechanisms driving this complex disease and accelerate the discovery of new therapies for people living with pancreatic cancer.”

NICE recommends nine digital treatment options for depression and anxiety

The National Institute for Health and Care Excellence (NICE) has recommended six digitally enabled therapies for adult patients with anxiety disorders and three digitally enabled therapies for adult patients with depression for use within the NHS while further data is gathered.

Bristol Myers Squibb and Viz.ai sign multi-year partnership for HCM device

Bristol Myers Squibb and Viz.ai, an AI-powered medical imaging company, have signed a deal to use AI to detect and triage patients with suspected hypertrophic cardiomyopathy (hcm).

Sooma receives FDA Breakthrough Device designation for depression therapy device

Finnish company Sooma medical has received breakthrough device designation by the FDA for its portable, at-home neuromodulation device to treat depression.

Elon Musk’s Neuralink rejected by FDA for human trials

The FDA has reportedly rejected a bid by Elon Musk’s Neuralink in which it proposed the initiation of human testing for its brain chip implants. The company has been working on brain implants that allow for a computer-brain interface, which could allegedly restore vision to the blind and help paralysed people to walk again.

AI Finds Liver Cancer Drug Candidate In Only 30 Days

A team of scientists have broken records with their new AI which has found a novel drug candidate for liver cancer in only 30 days

NICE recommends nine digital treatment options for depression and anxiety

Bristol Myers Squibb and Viz.ai sign multi-year partnership for HCM device

Sooma receives FDA Breakthrough Device designation for depression therapy device

Elon Musk’s Neuralink rejected by FDA for human trials

AI Finds Liver Cancer Drug Candidate In Only 30 Days

Pharmafocus

Categories

Social Footprints